{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:58:47Z","timestamp":1761947927362},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40273-013-0098-6","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T02:26:30Z","timestamp":1384395990000},"page":"1031-1050","source":"Crossref","is-referenced-by-count":10,"title":["A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection"],"prefix":"10.1007","volume":"31","author":[{"given":"Josephine","family":"Mauskopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,15]]},"reference":[{"key":"98_CR1","unstructured":"Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. Available from: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf . Accessed 29 Jul 2013."},{"issue":"4","key":"98_CR2","first-page":"a007161","volume":"2","author":"EJ Arts","year":"2012","unstructured":"Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161. doi: 10.1101\/cshperspect.a007161 .","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"98_CR3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jama.1993.03510040078033","volume":"270","author":"FJ Hellinger","year":"1993","unstructured":"Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270(4):474\u20138.","journal-title":"JAMA"},{"key":"98_CR4","doi-asserted-by":"crossref","unstructured":"Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ et al. Updates of lifetime costs of care and quality of life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64:183\u20139. doi: 10.1097\/QAI.0b013e3182973966 .","DOI":"10.1097\/QAI.0b013e3182973966"},{"issue":"2","key":"98_CR5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/COH.0b013e328343ad66","volume":"6","author":"V Cambiano","year":"2011","unstructured":"Cambiano V, Phillips AN. Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS. 2011;6(2):124\u201330. doi: 10.1097\/COH.0b013e328343ad66 .","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"98_CR6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/COH.0b013e3283384aed","volume":"5","author":"KN Simpson","year":"2010","unstructured":"Simpson KN. Economic modeling of HIV treatments. Curr Opin HIV AIDS. 2010;5(3):242\u20138. doi: 10.1097\/COH.0b013e3283384aed .","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"98_CR7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clinthera.2008.02.009","volume":"30","author":"R S\u00e1nchez-de la Rosa","year":"2008","unstructured":"S\u00e1nchez-de la Rosa R, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine\/tenofovir versus lamivudine\/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Clin Ther. 2008;30(2):372\u201381.","journal-title":"Clin Ther"},{"issue":"4","key":"98_CR8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/00365548.2010.545835","volume":"43","author":"PO Thuresson","year":"2011","unstructured":"Thuresson PO, Heeg B, Lescrauwaet B, Sennf\u00e4lt K, Alaeus A, Neubauer A. Cost-effectiveness of atazanavir\/ritonavir compared with lopinavir\/ritonavir in treatment-naive human immunodeficiency virus-1 patients in Sweden. Scand J Infect Dis. 2011;43(4):304\u201312.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"98_CR9","first-page":"197","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Colangeli V, di Biagio A, di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. 2011;3(1):197\u2013205.","journal-title":"Cost-effectiveness analysis of initial HIV treatment under Italian guidelines"},{"issue":"4","key":"98_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1310\/hct1004-233","volume":"10","author":"EE Elbasha","year":"2009","unstructured":"Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, et al. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin Trials. 2009;10(4):233\u201353.","journal-title":"HIV Clin Trials"},{"issue":"7","key":"98_CR11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/aid.2008.0254","volume":"25","author":"MA Chaudhary","year":"2009","unstructured":"Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. AIDS Res Hum Retrovir. 2009;25(7):679\u201389.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"2","key":"98_CR12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00019053-200927020-00006","volume":"27","author":"KN Simpson","year":"2009","unstructured":"Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27(2):159\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"98_CR13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-114-9-798","volume":"114","author":"KA Schulman","year":"1991","unstructured":"Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991;114(9):798\u2013802.","journal-title":"Ann Intern Med"},{"issue":"4","key":"98_CR14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00019053-200018040-00007","volume":"18","author":"AH Anis","year":"2000","unstructured":"Anis AH, Guh D, Hogg RS, Wang XH, Yip B, Craib KJ, et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV\/AIDS. Pharmacoeconomics. 2000;18(4):393\u2013404.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"98_CR15","first-page":"795","volume":"4","author":"AD Paltiel","year":"1991","unstructured":"Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4(8):795\u2013804.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"98_CR16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","volume":"158","author":"RP Walensky","year":"2013","unstructured":"Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84\u201392. doi: 10.7326\/0003-4819-158-2-201301150-00002 .","journal-title":"Ann Intern Med"},{"issue":"5","key":"98_CR17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40273-013-0048-3","volume":"31","author":"KN Simpson","year":"2013","unstructured":"Simpson KN, Pei PP, M\u00f6ller J, Baran RW, Dietz B, Woodward W, et al. Lopinavir\/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013;31(5):427\u201344. doi: 10.1007\/s40273-013-0048-3 .","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"98_CR18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1310\/WT81-MEM4-5C4L-CHPK","volume":"5","author":"KN Simpson","year":"2004","unstructured":"Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir\/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294\u2013304.","journal-title":"HIV Clin Trials"},{"issue":"1","key":"98_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00044011-200727010-00006","volume":"27","author":"KN Simpson","year":"2007","unstructured":"Simpson KN, Luo MP, Chumney EC, King MS, Brun S. Cost effectiveness of lopinavir\/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007;27(1):67\u201374.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"98_CR20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200727070-00001","volume":"27","author":"KN Simpson","year":"2007","unstructured":"Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir\/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007;27(7):443\u201352.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"98_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00044011-200727120-00002","volume":"27","author":"KN Simpson","year":"2007","unstructured":"Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir\/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007;27(12):807\u201317.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"98_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1310\/hct0904-225","volume":"9","author":"KN Simpson","year":"2008","unstructured":"Simpson KN, Roberts G, Hicks CB, Finnern HW. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008;9(4):225\u201337.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"98_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12325-008-0141-8","volume":"26","author":"KN Simpson","year":"2009","unstructured":"Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir\/ritonavir and atazanavir\u00a0+\u00a0ritonavir regimens in the CASTLE study. Adv Ther. 2009;26(2):185\u201393.","journal-title":"Adv Ther"},{"key":"98_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-7547-9-5","volume":"9","author":"KN Simpson","year":"2011","unstructured":"Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, et al. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc. 2011;9:5.","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"98_CR25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3111\/13696998.2012.691927","volume":"15","author":"KN Simpson","year":"2012","unstructured":"Simpson KN, Baran RW, Collomb D, Beck EJ, Van de Steen O, Dietz B. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir\/ritonavir (LPV\/r) and atazanavir plus ritonavir (ATV\u00a0+\u00a0RTV) based regimens for antiretroviral therapy (ART)-naive and -experienced United Kingdom patients in 2011. J Med Econ. 2012;15(4):796\u2013806.","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"98_CR26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/11587470-000000000-00000","volume":"28","author":"J Mauskopf","year":"2010","unstructured":"Mauskopf J, Brogan A, Martin S, Smets E. Cost effectiveness of darunavir\/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28(Suppl 1):83\u2013105.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"98_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAD.0b013e32834e87e6","volume":"26","author":"J Mauskopf","year":"2012","unstructured":"Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012;26(3):355\u201364.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"98_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/11587480-000000000-00000","volume":"28","author":"K Moeremans","year":"2010","unstructured":"Moeremans K, Annemans L, L\u00f6thgren M, Allegri G, Wyffels V, Hemmet L, et al. Cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):107\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"98_CR29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11587500-000000000-00000","volume":"28","author":"K Moeremans","year":"2010","unstructured":"Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):147\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"98_CR30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/11587490-000000000-00000","volume":"28","author":"A Brogan","year":"2010","unstructured":"Brogan A, Mauskopf J, Talbird SE, Smets E. US cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010;28(Suppl 1):129\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"98_CR31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1310\/REJM-TAFW-0A7T-97UA","volume":"6","author":"J Hornberger","year":"2005","unstructured":"Hornberger J, Green J, Wintfeld N, Cavassini M, Rockstroh J, Giuliani G, et al. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. HIV Clin Trials. 2005;6(2):92\u2013102.","journal-title":"HIV Clin Trials"},{"issue":"4","key":"98_CR32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1310\/hct0804-235","volume":"8","author":"X Badia","year":"2007","unstructured":"Badia X, Liz\u00e1n L, Magaz S, Sanz AC, Green J, Serrano D. Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV\/AIDS. HIV Clin Trials. 2007;8(4):235\u201345.","journal-title":"HIV Clin Trials"},{"issue":"6","key":"98_CR33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00019053-199406060-00008","volume":"6","author":"K Simpson","year":"1994","unstructured":"Simpson K, Hatziandreu EJ, Andersson F, Shakespeare A, Oleksy I, Tosteson AN. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4\u00a0+\u00a0counts less than 300\/microliters in 5 European countries. Pharmacoeconomics. 1994;6(6):553\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"98_CR34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2165\/00019053-199712010-00006","volume":"12","author":"JV Chancellor","year":"1997","unstructured":"Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine\/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997;12(1):54\u201366.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"98_CR35","first-page":"1004","volume":"4","author":"J Mauskopf","year":"1998","unstructured":"Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998;4(7):1004\u201312.","journal-title":"Am J Manag Care"},{"issue":"3","key":"98_CR36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1524-4733.2000.33006.x","volume":"3","author":"AK Biddle","year":"2000","unstructured":"Biddle AK, Simpson KN. Modeling the use of triple combination therapy in five countries: nevirapine, zidovudine, and didanosine. Value Health. 2000;3(3):186\u2013201.","journal-title":"Value Health"},{"issue":"13","key":"98_CR37","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0149-2918(10)80026-8","volume":"32","author":"S Moreno","year":"2010","unstructured":"Moreno S, Gonz\u00e1lez J, Lekander I, Mart\u00ed B, Oyag\u00fcez I, S\u00e1nchez-de la Rosa R, et al. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clin Ther. 2010;32(13):2232\u201345.","journal-title":"Clin Ther"},{"issue":"5","key":"98_CR38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jval.2011.01.009","volume":"14","author":"AJ Brogan","year":"2011","unstructured":"Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States. Value Health. 2011;14(5):657\u201364.","journal-title":"Value Health"},{"key":"98_CR39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1478-7547-5-15","volume":"5","author":"GA Hubben","year":"2007","unstructured":"Hubben GA, Bos JM, Veltman-Starkenburg CA, Stegmeijer S, Finnern HW, Kappelhoff BS, et al. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc. 2007;5:15. doi: 10.1186\/1478-7547-5-15 .","journal-title":"Cost Eff Resour Alloc"},{"issue":"12","key":"98_CR40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","volume":"126","author":"JW Mellors","year":"1997","unstructured":"Mellors JW, Mu\u00f1oz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4\u00a0+\u00a0lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946\u201354.","journal-title":"Ann Intern Med"},{"issue":"12","key":"98_CR41","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.296.12.1498","volume":"296","author":"B Rodr\u00edguez","year":"2006","unstructured":"Rodr\u00edguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296(12):1498\u2013506. doi: 10.1001\/jama.296.12.1498 .","journal-title":"JAMA"},{"issue":"11","key":"98_CR42","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJM200103153441108","volume":"344","author":"KA Freedberg","year":"2001","unstructured":"Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"98_CR43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.qai.0000160406.08924.a2","volume":"39","author":"PE Sax","year":"2005","unstructured":"Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39(1):69\u201377.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"98_CR44","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1524-4733.2010.00798.x","volume":"13","author":"I Contreras-Hernandez","year":"2010","unstructured":"Contreras-Hernandez I, Becker D, Chancellor J, K\u00fchne F, Mould-Quevedo J, Vega G, et al. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. Value Health. 2010;13(8):903\u201314.","journal-title":"Value Health"},{"issue":"2","key":"98_CR45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1310\/hct1102-80","volume":"11","author":"FC K\u00fchne","year":"2010","unstructured":"K\u00fchne FC, Chancellor J, Mollon P, Myers DE, Louie M, Powderly WG. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clin Trials. 2010;11(2):80\u201399.","journal-title":"HIV Clin Trials"},{"issue":"4","key":"98_CR46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00019053-200220040-00001","volume":"20","author":"A Richter","year":"2002","unstructured":"Richter A, Hauber B, Simpson K, Mauskopf JA, Yin D. A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens. Pharmacoeconomics. 2002;20(4):215\u201324.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"98_CR47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1468-1293.2001.00048.x","volume":"2","author":"AH Miners","year":"2001","unstructured":"Miners AH, Sabin CA, Trueman P, Youle M, Mocroft A, Johnson M, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2001;2(1):52\u20138.","journal-title":"HIV Med"},{"issue":"2","key":"98_CR48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3111\/13696998.2011.554932","volume":"14","author":"MS Broder","year":"2011","unstructured":"Broder MS, Chang EY, Bentley TG, Juday T, Uy J. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected patients in the United States. J Med Econ. 2011;14(2):167\u201378.","journal-title":"J Med Econ"},{"issue":"9","key":"98_CR49","doi-asserted-by":"crossref","first-page":"e44774","DOI":"10.1371\/journal.pone.0044774","volume":"7","author":"F Arag\u00e3o","year":"2012","unstructured":"Arag\u00e3o F, Vera J, Vaz Pinto I. Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. PLoS One. 2012;7(9):e44774.","journal-title":"PLoS One"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0098-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-013-0098-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0098-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:44:52Z","timestamp":1559490292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-013-0098-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s40273-013-0098-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}